AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the ...
Cautious Optimism: Amgen’s Uplizna Shows Promise but Limited Immediate Impact on Valuation
Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.
Amgen Reports Positive Phase 3 Data For Uplizna In Generalized Myasthenia Gravis
Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...
WGN-TV3d
AMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
Oct. 15, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of positive top-line results from the Phase 3 MINT trial evaluating the efficacy and safety of UPLIZNA ...
Investing3d
Amgen's UPLIZNA shows promise in myasthenia gravis trial
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG).
Investing3d
Amgen's UPLIZNA shows promise in myasthenia gravis trial
THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN) has revealed positive results from its Phase 3 MINT trial for UPLIZNA (inebilizumab-cdon), a treatment for adults with generalized myasthenia gravis (gMG).